Small-cap stock under ₹50 jumps 7% despite weak trends on Dalal Street; here's why | Target price, stop-loss

Here are all the details about Sudarshan Pharma listing on NSE main board and other business updates.Sudarshan Pharma Industries NSE main board listingThe company successfully migrated from SME Platform of BSE to Capital Market Segment (main board) of NSE, as per its latest stock exchange filing.“The equity shares of the Company shall be listed and admitted to dealings on the Exchange (Capita Market Segment) w.e.f.

October 27, 2026 pursuant to migration from SME Platform of BSE,” read Sudarshan Pharma’s exchange filing released earlier.Sudarshan Pharma upcoming Q2 resultsThe Maharashtra-headquartered pharmaceutical firm’s board of directors meeting is scheduled for Thursday, October 29.The company’s board of directors is scheduled to meet, consider and announce results for the second quarter of financial year 2026-27.

Apart from Q2FY27 result announcement, the pharma company will also consider and approve fund raising proposal.Sudarshan Pharma fund raising proposalThe board may consider and approve fundraising proposal “by way of issue of one or more of instruments comprising of equity shares, convertible securities of any other description or warrants or debt securities.” The fund raise may be executed through private placement / preferential issue / Qualified Institutions Placement or such other methods or combinations thereof.Sudarshan Pharma Industries share price trendThe pharma stock closed 7.83% higher on BSE at ₹37.61 per share with a market capitalisation of ₹938.97 crore.

Its share price value has surged 12.43% in one week, 26.67% in one month and around 40.58% in 2026 so far. The stock has delivered around 61.77% return in one year.Sudarshan Pharma stock jumps 61.7% in one year: Check technical outlookThe stock closed above resistance level of ₹37 per share, which indicates a bullish momentum. An opening for ₹40 per share, can trigger further upside in the stock, according to Mahesh M Ojha, VP - Research and Business Development at KC Securities. The expert gave a stop loss of ₹31.80 per share.